Pipeline Overview

We have built a portfolio of targeted therapies for cancer with the potential to address significant clinical needs. Our pivotal-stage clinical program, inodiftagene vixteplasmid, is a gene therapy being developed for the treatment of early stage bladder cancer. In addition, we have preclinical programs with small molecules targeting RAS and PDE10/ß-catenin.